U.S. markets closed
  • S&P Futures

    4,219.75
    +6.00 (+0.14%)
     
  • Dow Futures

    33,820.00
    +59.00 (+0.17%)
     
  • Nasdaq Futures

    14,138.25
    +8.25 (+0.06%)
     
  • Russell 2000 Futures

    2,284.90
    +4.00 (+0.18%)
     
  • Crude Oil

    73.64
    -0.02 (-0.03%)
     
  • Gold

    1,787.60
    +4.70 (+0.26%)
     
  • Silver

    25.96
    -0.07 (-0.25%)
     
  • EUR/USD

    1.1916
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.4840
    +0.0340 (+2.34%)
     
  • Vix

    17.89
    -2.81 (-13.57%)
     
  • GBP/USD

    1.3918
    -0.0015 (-0.10%)
     
  • USD/JPY

    110.3900
    +0.0920 (+0.08%)
     
  • BTC-USD

    32,795.39
    -2,302.48 (-6.56%)
     
  • CMC Crypto 200

    790.37
    -59.97 (-7.05%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,822.28
    +811.35 (+2.90%)
     

Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March:

H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 am (Eastern Time) a pre-recorded company presentation will become available for on-demand viewing.
Roth Capital Partners Annual Conference, Live fireside chat on Monday, March 15, 2021, at 9:00 am (Eastern Time).
Oppenheimer & Co. 31st Annual Healthcare Conference, Company presentation on Tuesday, March 16, 2021 at 9:20 am (Eastern Time).
Maxim Group Emerging Growth Virtual Conference on Wednesday, March 17, 2021 at 10:00 am (Eastern Time) a pre-recorded company presentation will become available for on-demand viewing.

A link to the webcast of each event will be available on the News and Events section of the Company’s website at antibethera.com. Following the events, a replay of the webcasts will be available on the website for 90 days.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. Antibe’s current pipeline includes three assets that seek to overcome the gastrointestinal ("GI") ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe’s lead drug, otenaproxesul, is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease ("IBD"), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005297/en/

Contacts

Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-922-3460
christina@antibethera.com

Stern Investor Relations
Courtney Turiano
+1 212-362-1200
courtney.turiano@sternir.com